Xin Lang Cai Jing·2025-09-15 02:06Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, specializing in I-IV phase clinical trials, data management, and medical testing services [1][2] - The company was established on December 15, 2004, and went public on August 17, 2012 [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.46 billion yuan in dividends since its A-share listing, with 1.15 billion yuan distributed over the last three years [3] Stock Performance - As of September 15, Tiger Med's stock price increased by 2.02% to 62.24 yuan per share, with a market capitalization of 53.59 billion yuan [1] - Year-to-date, the stock has risen by 14.58%, but it has seen a decline of 7.37% over the last five trading days and 10.45% over the last 20 days [1] Shareholder Structure - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3]